Restrictions apply. Apidra Tools and Resources Take a more proactive approach to managing your blood sugar by accessing tools to help you stay in control. It is not known if APIDRA is safe or effective in children less than 4 years of age with type 1 diabetes or in children with type 2 diabetes. When used as a mealtime insulin, Apidra should be given within 15 minutes before or within 20 minutes after starting a meal.
|Published (Last):||3 August 2007|
|PDF File Size:||11.68 Mb|
|ePub File Size:||9.47 Mb|
|Price:||Free* [*Free Regsitration Required]|
See if your patients are eligible. When used as a mealtime insulin, the dose of Apidra should be given within 15 minutes before or within 20 minutes after starting a meal. Apidra may be infused subcutaneously by external insulin infusion pumps. Important Safety Information Contraindications Apidra is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Apidra or any of its excipients.
Warnings and Precautions Insulin pens and needles must never be shared between patients, even if the needle is changed. Do NOT reuse needles.
Monitor blood glucose in all patients treated with insulin. Modify insulin regimens only under medical supervision. Changes in insulin regimen including, strength, manufacturer, type, injection site or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Dosing should be individualized based on patient characteristics and lifestyle.
Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia; sudden change in the injection site to unaffected area has been reported to result in hypoglycemia.
Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia. Hypoglycemia is the most common adverse reaction associated with insulins, including Apidra, and maybe life-threatening. To avoid medication errors between APIDRA and other insulins, instruct patients to always check the insulin label before each injection.
All insulin products, including Apidra, can cause hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Use caution in patients who may be at risk for hypokalemia. Severe life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including APIDRA. If hypersensitivity reactions occur, discontinue APIDRA, treat per standard of care and monitor until symptoms and signs resolve.
Fluid retention and heart failure can occur with concomitant use of thiazolidinediones TZDs with insulin. Observe for signs and symptoms of heart failure. Consider dosage reduction or discontinuation of TZD if heart failure occurs. Malfunction of the insulin pump or insulin infusion set or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis.
Patients using insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure. Adverse Reactions Adverse reactions commonly associated with Apidra include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, and weight gain. Drug Interactions Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose.
The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs e. To help ensure an accurate dose each time, patients should follow the steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose.
Important Safety Information for Apidra Use in Pump Inform patients to replace the infusion sets reservoir, tubing, and catheter and the Apidra in the reservoir at least every 48 hours and select a new infusion site. Pump failure or insulin infusion set or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis.
Prompt identification and correction of the cause is necessary. Patients using a pump must be trained to administer insulin by injection and have alternative insulin therapy available in case of pump system failure.
Click here for Full Prescribing Information for Apidra. Click here for information on Sharps Medical Waste Disposal. Only people without prescription medication insurance can apply for this offer. Void where prohibited by law. Offer is valid for one fill per month. When using the Insulins Valyou Savings Card, prices are guaranteed for 12 consecutive monthly fills. The Insulins Valyou Savings Program applies to the cost of medication. There are other relevant costs associated with overall treatment.
Important to note that if you have an Affordable Care Health Care Exchange plan, you may still be qualified to receive and use this savings card. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke or amend these programs without notice. Diabetes Obes Metab. Exp Clin Endocrinol Diabetes.
RECENT MAJOR CHANGES
Generalized allergy to insulin may cause whole body rash including pruritus , dyspnea, wheezing, hypotension, tachycardia, or diaphoresis. In controlled clinical trials up to 12 months duration, potential systemic allergic reactions were reported in 79 of patients 4. During these trials, treatment with Apidra was permanently discontinued in 1 of patients due to a potential systemic allergic reaction. Injection Site Reactions As with any insulin therapy, patients taking Apidra may experience redness, swelling, or itching at the site of injection. These minor reactions usually resolve in a few days to a few weeks, but in some occasions may require discontinuation of Apidra. In some instances, these reactions may be related to factors other than insulin, such as irritants in a skin cleansing agent or poor injection technique.
Apidra® is a fast-acting and flexible mealtime insulin
There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [see Clinical Considerations ]. Animal reproduction studies have been conducted with insulin glulisine in rats and rabbits using regular human insulin as a comparator. The effects did not differ from those observed with subcutaneous regular human insulin [see Data ]. The estimated background risk of miscarriage for the indicated population is unknown. In the U.